Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Yung‐Kuo Lee"'
Autor:
Tung‐Yuan Chen, Chin‐Wen Hsu, Yee‐Phoung Chang, Min‐Tsung Wang, Yueh‐Jung Wu, Ching‐Hsien Wang, Kuan‐Yu Wang, Tian‐Huei Chu, Yung‐Kuo Lee
Publikováno v:
Clinical Case Reports, Vol 11, Iss 7, Pp n/a-n/a (2023)
Key Clinical Message Temporal percutaneous transhepatic duodenum drainage (PTDD) seems to be effective in the treatment of postoperative afferent loop syndrome (ALS) following transverse loop colostomy for obstructive colorectal cancer. Abstract Mana
Externí odkaz:
https://doaj.org/article/3d7a350b0ae2411ea6ebe747483237b9
Autor:
Yu-Ting Su, Jia-Shing Chen, Kuo-Chung Lan, Yung-Kuo Lee, Tian-Huei Chu, Yu-Cheng Ho, Cheng-Chun Wu, Fu-Jen Huang
Publikováno v:
Biomedicines, Vol 11, Iss 3, p 907 (2023)
The clinical use of mifepristone for medical abortions has been established in 1987 in France and since 2000 in the United States. Mifepristone has a limited medical period that lasts n = 3, mifepristone n = 3). When we performed a gene set enrichmen
Externí odkaz:
https://doaj.org/article/48a5b916db764e42afa74dc9c504ba4f
Autor:
Yung-Kuo Lee, Wen-Chiu Chang, Ekambaranellore Prakash, Yu-Ju Peng, Zhi-Jay Tu, Chun-Hung Lin, Pang-Hung Hsu, Chuan-Fa Chang
Publikováno v:
Viruses, Vol 14, Iss 2, p 330 (2022)
An outbreak of SARS-CoV-2 coronavirus (COVID-19) first detected in Wuhan, China, has created a public health emergency all over the world. The pandemic has caused more than 340 million confirmed cases and 5.57 million deaths as of 23 January 2022. Al
Externí odkaz:
https://doaj.org/article/055dda1f273244c0856aaa3daf33c96a
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e82478 (2013)
Multidrug resistance (MDR), an unfavorable factor compromising the treatment efficacy of anticancer drugs, involves the upregulation of ATP binding cassette (ABC) transporters and induction of galectin-3 signaling. Galectin-3 plays an anti-apoptotic
Externí odkaz:
https://doaj.org/article/3659aa9837254b3aa3da4f0811ec70bd
Autor:
Shiow-Jyu Tzou, I-Hung Chen, Tian-Huei Chu, De-Ming Chian, Fu-Kang Wang, Yung-Kuo Lee, Chou-Yuan Ko
Publikováno v:
Medical Science Monitor. 29
Autor:
Pei-Chun Shih, Hsin-Pao Chen, Ching-Cheng Hsu, Chung-Hsien Lin, Chou-Yuan Ko, Chao-Wen Hsueh, Cheng-Yi Huang, Tian-Huei Chu, Cheng-Chun Wu, Yu-Cheng Ho, Ngoc Uyen Nhi Nguyen, Shih-Chung Huang, Cheng-Chieh Fang, Shiow-Jyu Tzou, Yueh-Jung Wu, Tung-Yuan Chen, Chuan-Fa Chang, Yung-Kuo Lee
Publikováno v:
Environmental Pollution. 327:121476
Autor:
Shih-Chung Huang, Chao-Cheng Huang, Chou-Yuan Ko, Cheng-Yi Huang, Ching-Han Liu, Yung-Kuo Lee, Tung-Yuan Chen, Chao-Wen Hsueh, Shiow-Jyu Tzou, Ming-Hong Tai, Tsung-Hui Hu, Ming-Chao Tsai, Wen-Chin Lee, Yu-Cheng Ho, Cheng-Chun Wu, Yi-Chen Chang, Jung-Jui Chang, Kai-Hsi Liu, Chiao-Ching Li, Zhi-Hong Wen, Chen-Lin Chang, Tian-Huei Chu
Publikováno v:
Gene. 865:147331
Autor:
Tian-Huei Chu, Chou-Yuan Ko, Po-Han Tai, Yi-Chen Chang, Chao-Cheng Huang, Tung-Yang Wu, Hoi-Hung Chan, Ping-Hsuan Wu, Chien-Hui Weng, Yu-Wei Lin, Mei-Lang Kung, Cheng-Chieh Fang, Jian-Ching Wu, Zhi-Hong Wen, Yung-Kuo Lee, Tsung-Hui Hu, Ming-Hong Tai
Publikováno v:
The Journal of biological chemistry. 298(10)
Leukocyte cell-derived chemotaxin 2 (LECT2) acts as a tumor suppressor in hepatocellular carcinoma (HCC). However, the antineoplastic mechanism of LECT2, especially its influence on hepatic cancer stem cells (CSCs), remains largely unknown. In The Ca
Autor:
Chou-Yuan Ko, Tian-Huei Chu, Ching-Cheng Hsu, Hsin-Pao Chen, Shih-Chung Huang, Chen-Lin Chang, Shiow-Jyu Tzou, Tung-Yuan Chen, Chia-Chen Lin, Pei-Chun Shih, Chung-Hsien Lin, Chuan-Fa Chang, Yung-Kuo Lee
Publikováno v:
Journal of Personalized Medicine; Volume 12; Issue 3; Pages: 401
Sialylation of glycoproteins is modified by distinct sialyltransferases such as ST3Gal, ST6Gal, ST6GalNAc, or ST8SIA with α2,3-, α2,6-, or α2,8-linkages. Alteration of these sialyltransferases causing aberrant sialylation is associated with the pr
Publikováno v:
Oncotarget
Phthalates are widely used as plasticizers. Humans can be exposed to phthalates through ingestion, inhalation, or treatments that release di(2-ethylhexyl) phthalate (DEHP) and its metabolite, mono(2-ehylhexyl) phthalate (MEHP), into the body from pol